文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

在一名成年起病的痛性周围神经病、卡马西平反应性患者中发现一种新型的钠通道Nav1.7 功能获得性突变。

A novel gain-of-function Na1.7 mutation in a carbamazepine-responsive patient with adult-onset painful peripheral neuropathy.

机构信息

1 Department of Neurology, Yale University School of Medicine, New Haven, CT, USA.

2 Center for Neuroscience and Regeneration Research, Veterans Affairs Medical Center, West Haven, CT, USA.

出版信息

Mol Pain. 2018 Jan-Dec;14:1744806918815007. doi: 10.1177/1744806918815007. Epub 2018 Nov 5.


DOI:10.1177/1744806918815007
PMID:30392441
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6856981/
Abstract

Voltage-gated sodium channel Na1.7 is a threshold channel in peripheral dorsal root ganglion (DRG), trigeminal ganglion, and sympathetic ganglion neurons. Gain-of-function mutations in Na1.7 have been shown to increase excitability in DRG neurons and have been linked to rare Mendelian and more common pain disorders. Discovery of Na1.7 variants in patients with pain disorders may expand the spectrum of painful peripheral neuropathies associated with a well-defined molecular target, thereby providing a basis for more targeted approaches for treatment. We screened the genome of a patient with adult-onset painful peripheral neuropathy characterized by severe burning pain and report here the new Na1.7-V810M variant. Voltage-clamp recordings were used to assess the effects of the mutation on biophysical properties of Na1.7 and the response of the mutant channel to treatment with carbamazepine (CBZ), and multi-electrode array (MEA) recordings were used to assess the effects of the mutation on the excitability of neonatal rat pup DRG neurons. The V810M variant increases current density, shifts activation in a hyperpolarizing direction, and slows kinetics of deactivation, all gain-of-function attributes. We also show that DRG neurons that express the V810M variant become hyperexcitable. The patient responded to treatment with CBZ. Although CBZ did not depolarize activation of the mutant channel, it enhanced use-dependent inhibition. Our results demonstrate the presence of a novel gain-of-function variant of Na1.7 in a patient with adult-onset painful peripheral neuropathy and the responsiveness of that patient to treatment with CBZ, which is likely due to the classical mechanism of use-dependent inhibition.

摘要

电压门控钠离子通道 Na1.7 是外周背根神经节 (DRG)、三叉神经节和交感神经节神经元中的阈通道。Na1.7 的功能获得性突变已被证明可增加 DRG 神经元的兴奋性,并与罕见的孟德尔遗传病和更常见的疼痛障碍有关。在疼痛障碍患者中发现 Na1.7 变体可能会扩大与明确分子靶标相关的痛性周围神经病变谱,从而为更有针对性的治疗方法提供基础。我们筛选了一名成年起病的痛性周围神经病患者的基因组,该患者的特征为严重灼痛,并在此报告新的 Na1.7-V810M 变体。我们使用电压钳记录来评估该突变对 Na1.7 的生物物理特性的影响,以及对卡马西平 (CBZ) 治疗的突变通道的反应,并使用多电极阵列 (MEA) 记录来评估该突变对新生大鼠 DRG 神经元兴奋性的影响。V810M 变体增加了电流密度,使激活向超极化方向偏移,并使失活动力学减慢,所有这些都是功能获得的特征。我们还表明,表达 V810M 变体的 DRG 神经元变得过度兴奋。该患者对 CBZ 治疗有反应。尽管 CBZ 没有使突变通道的激活去极化,但它增强了使用依赖性抑制。我们的结果表明,在一名成年起病的痛性周围神经病患者中存在 Na1.7 的新型功能获得性变体,并且该患者对 CBZ 治疗有反应,这可能是由于使用依赖性抑制的经典机制。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd97/6856981/ddaecb0ac4e2/10.1177_1744806918815007-fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd97/6856981/01328b624981/10.1177_1744806918815007-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd97/6856981/7afa41214f65/10.1177_1744806918815007-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd97/6856981/7e99bd36d99f/10.1177_1744806918815007-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd97/6856981/7ceb15b4df95/10.1177_1744806918815007-fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd97/6856981/ddaecb0ac4e2/10.1177_1744806918815007-fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd97/6856981/01328b624981/10.1177_1744806918815007-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd97/6856981/7afa41214f65/10.1177_1744806918815007-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd97/6856981/7e99bd36d99f/10.1177_1744806918815007-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd97/6856981/7ceb15b4df95/10.1177_1744806918815007-fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd97/6856981/ddaecb0ac4e2/10.1177_1744806918815007-fig5.jpg

相似文献

[1]
A novel gain-of-function Na1.7 mutation in a carbamazepine-responsive patient with adult-onset painful peripheral neuropathy.

Mol Pain. 2018-11-5

[2]
The Novel Activity of Carbamazepine as an Activation Modulator Extends from Na1.7 Mutations to the Na1.8-S242T Mutant Channel from a Patient with Painful Diabetic Neuropathy.

Mol Pharmacol. 2018-8-22

[3]
Nav1.7-A1632G Mutation from a Family with Inherited Erythromelalgia: Enhanced Firing of Dorsal Root Ganglia Neurons Evoked by Thermal Stimuli.

J Neurosci. 2016-7-13

[4]
Small-fiber neuropathy Nav1.8 mutation shifts activation to hyperpolarized potentials and increases excitability of dorsal root ganglion neurons.

J Neurosci. 2013-8-28

[5]
Differential effect of D623N variant and wild-type Na(v)1.7 sodium channels on resting potential and interspike membrane potential of dorsal root ganglion neurons.

Brain Res. 2013-7-11

[6]
Gain-of-function mutations in sodium channel Na(v)1.9 in painful neuropathy.

Brain. 2014-4-27

[7]
Increased Resurgent Sodium Currents in Nav1.8 Contribute to Nociceptive Sensory Neuron Hyperexcitability Associated with Peripheral Neuropathies.

J Neurosci. 2019-1-7

[8]
I current stabilizes excitability in rodent DRG neurons and reverses hyperexcitability in a nociceptive neuron model of inherited neuropathic pain.

J Physiol. 2023-12

[9]
The G1662S NaV1.8 mutation in small fibre neuropathy: impaired inactivation underlying DRG neuron hyperexcitability.

J Neurol Neurosurg Psychiatry. 2013-9-4

[10]
DRG Voltage-Gated Sodium Channel 1.7 Is Upregulated in Paclitaxel-Induced Neuropathy in Rats and in Humans with Neuropathic Pain.

J Neurosci. 2017-12-18

引用本文的文献

[1]
Enhancing Chemical Stability and Bioavailability of Aneratrigine Capsules via Dry Granulation: Addressing Stability Challenges in Sodium Bicarbonate-Containing Formulations for Clinical Development.

Pharmaceutics. 2025-8-12

[2]
Scorpion Neurotoxin Syb-prII-1 Exerts Analgesic Effect through Nav1.8 Channel and MAPKs Pathway.

Int J Mol Sci. 2022-6-25

[3]
Mechanisms Underlying the Selective Therapeutic Efficacy of Carbamazepine for Attenuation of Trigeminal Nerve Injury Pain.

J Neurosci. 2021-10-27

[4]
Targeted Therapies for Hereditary Peripheral Neuropathies: Systematic Review and Steps Towards a 'treatabolome'.

J Neuromuscul Dis. 2021

本文引用的文献

[1]
Na1.7 as a Pharmacogenomic Target for Pain: Moving Toward Precision Medicine.

Trends Pharmacol Sci. 2018-1-20

[2]
Rare NaV1.7 variants associated with painful diabetic peripheral neuropathy.

Pain. 2018-3

[3]
Old Friends With New Faces: Are Sodium Channel Blockers the Future of Adjunct Pain Medication Management?

J Pain. 2017-8-24

[4]
Reverse pharmacogenomics: carbamazepine normalizes activation and attenuates thermal hyperexcitability of sensory neurons due to Na 1.7 mutation I234T.

Br J Pharmacol. 2017-7-30

[5]
Sodium channels in pain disorders: pathophysiology and prospects for treatment.

Pain. 2017-4

[6]
Nav1.7-A1632G Mutation from a Family with Inherited Erythromelalgia: Enhanced Firing of Dorsal Root Ganglia Neurons Evoked by Thermal Stimuli.

J Neurosci. 2016-7-13

[7]
Pharmacological reversal of a pain phenotype in iPSC-derived sensory neurons and patients with inherited erythromelalgia.

Sci Transl Med. 2016-4-20

[8]
Pharmacotherapy for Pain in a Family With Inherited Erythromelalgia Guided by Genomic Analysis and Functional Profiling.

JAMA Neurol. 2016-6-1

[9]
Subtype-Selective Small Molecule Inhibitors Reveal a Fundamental Role for Nav1.7 in Nociceptor Electrogenesis, Axonal Conduction and Presynaptic Release.

PLoS One. 2016-4-6

[10]
Inherited erythromelalgia due to mutations in SCN9A: natural history, clinical phenotype and somatosensory profile.

Brain. 2016-2-26

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索